Yoonjeong Cha received her B.S. in Computer Science and Molecular Biology from Massachusetts Institute of Technology in 2015. In 2014, she started at Immuneering Corporation as a computational biology analyst and was later promoted to Sr. Director of Computational Biology in 2021. In 2023, Ms. Cha co-founded Alleo Labs, an early-stage biotech company focused on developing precision medicine for CNS diseases using machine learning. Her research topics mainly include machine learning, computational biology, Alzheimer's disease, Parkinson's disease, and other neurological disorders.

Dr. Mohamedi N. Kagalwala received his Ph.D. in Biochemistry and Molecular Biology from the Southern Illinois University School of Medicine. Dr. Kagalwala completed postdoctoral fellowships at MD Anderson Cancer Center and the Salk Institute. In 2020, he moved to Immuneering Corporation as Sr. Director of Neuroscience. Later, Dr. Kagalwala co-founded Alleo Labs, an early-stage biotech company focused on developing precision medicine for CNS diseases. His research topics mainly include Alzheimer's disease, Parkinson's disease, and other neurological disorders.

Dr. Jermaine Ross co-founded Alleo Labs in 2023 and serves as CEO and president. Dr. Ross brings years of industry experience in drug discovery and machine learning from his previous executive role as Vice President and Head of Neuroscience at Immuneering Corporation (NASDAQ: IMRX), which he co-led to a IPO in 2021. He received his bachelor’s degree from the University of Michigan in Molecular, Cellular, and Developmental Biology and holds a doctoral degree in Neuroscience from Brown University. Dr. Ross also trained as a neuroscientist and computational biologist at the National Institutes of Health for over 10 years. He is also a board member of the Alzheimer’s Association in New York City and is a William H. Gates Sr. Fellow in the Alzheimer's Disease Data Initiative.